Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / CASI - CASI renews distribution agreement for Evomela in China

CASI - CASI renews distribution agreement for Evomela in China

CASI Pharmaceuticals Inc.
CASI Pharmaceuticals (NASDAQ:CASI) renewed an exclusive distribution agreement under which China Resources Pharmaceutical Commercial Group International Trading Co. will continue to be the sole distributor of Evomela (melphalan) for Injection in China. Evomela is used as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. "EVOMELA has shown rapid revenue growth in the past three years and reached $30 million in 2021," said CASI's Global President Larry Zhang. CASI +3.41% premarket to $0.91

For further details see:

CASI renews distribution agreement for Evomela in China
Stock Information
Company Name: CASI Pharmaceuticals Inc.
Stock Symbol: CASI
Market: NASDAQ
Website: casipharmaceuticals.com
Menu
CASI CASI Quote CASI Short CASI News CASI Articles CASI Message Board
Get CASI Alerts

News, Short Squeeze, Breakout and More Instantly...